Literature DB >> 22231692

Impact of participation in randomized trials on outcome following surgery for gastro-oesophageal reflux.

C Engström1, G G Jamieson, P G Devitt, T Irvine, D I Watson.   

Abstract

BACKGROUND: Patients may be unwilling to participate in clinical trials if they perceive risks. Outcomes were evaluated following surgery for gastro-oesophageal reflux in patients recruited to randomized trials compared with patients not in trials.
METHODS: This study compared outcomes of patients who had surgery for reflux within or outside randomized trials between 1994 and 2009. The choice of procedure outside each trial was according to surgeon or patient preference. Clinical outcomes were determined 1 and 5 years after surgery using a standardized questionnaire, with analogue scales to assess heartburn, dysphagia and overall satisfaction. Subgroup analysis was undertaken for those aged less than 75 years undergoing laparoscopic Nissen fundoplication.
RESULTS: Some 417 patients entered six randomized trials evaluating surgery for reflux and 981 underwent surgery outside the trials. The trial group contained a higher proportion of men and younger patients, and patients in trials were more likely to have undergone Nissen fundoplication. At 1 year, patients in the trials had slightly lower heartburn scores and less abdominal bloating, but otherwise similar outcomes to those not in the trials. At 5 years there were no differences, except for a slightly higher dysphagia score for liquids in the trial group. For the subgroup analysis, demographic data were similar for both groups. There were no differences at 1 year, but at 5 years patients enrolled in the trials had higher scores for dysphagia for liquids and heartburn. All of the statistically significant differences were thought unlikely to be clinically relevant.
CONCLUSION: Participation in a randomized trial assessing surgery for reflux did not influence outcomes.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22231692     DOI: 10.1002/bjs.8666

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).

Authors:  Eelke Toxopeus; Maartje van der Schaaf; Jan van Lanschot; Jesper Lagergren; Pernilla Lagergren; Ate van der Gaast; Bas Wijnhoven
Journal:  Ann Surg Oncol       Date:  2018-06-12       Impact factor: 5.344

2.  Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Authors:  Clara Natoli; Patrizia Vici; Isabella Sperduti; Antonino Grassadonia; Giancarlo Bisagni; Nicola Tinari; Andrea Michelotti; Germano Zampa; Stefania Gori; Luca Moscetti; Michele De Tursi; Michele Panebianco; Maria Mauri; Ilaria Ferrarini; Laura Pizzuti; Corrado Ficorella; Riccardo Samaritani; Lucia Mentuccia; Stefano Iacobelli; Teresa Gamucci
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-20       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.